Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases. Inspired by patients, Synspira is focused on developing a rationally designed portfolio of products that can make a life-changing impact and improve the quality of life of patients. Synspira is working to advance two novel products (SNSP113 and SNSP003) intended to provide better clinical outcomes and reduce treatment burden in pulmonary disease as well as malabsorption syndromes and exocrine pancreatic insufficiency. SNSP113, Synspira’s lead product, is in a Phase 2 clinical study in people with cystic fibrosis. Synspira is a privately held company headquartered in Framingham, MA.